Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

631 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally.
van Schooten TS, Derks S, Jiménez-Martí E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O'Connor JM, Esteso F, Farrés J, Mas JM, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T; members of LEGACy consortium. van Schooten TS, et al. Among authors: cervantes a. BMC Cancer. 2022 Jun 13;22(1):646. doi: 10.1186/s12885-022-09689-9. BMC Cancer. 2022. PMID: 35692051 Free PMC article.
Unmet needs and challenges in gastric cancer: the way forward.
Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, Van Cutsem E, van de Velde C, Cervantes A. Lordick F, et al. Among authors: cervantes a. Cancer Treat Rev. 2014 Jul;40(6):692-700. doi: 10.1016/j.ctrv.2014.03.002. Epub 2014 Mar 13. Cancer Treat Rev. 2014. PMID: 24656602 Free article. Review.
Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment.
Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A. Llorca-Cardeñosa MJ, et al. Among authors: cervantes a. Oncotarget. 2016 Sep 27;7(39):63424-63436. doi: 10.18632/oncotarget.11520. Oncotarget. 2016. PMID: 27566570 Free PMC article.
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN. Meulendijks D, et al. Among authors: cervantes a. Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9. Clin Cancer Res. 2017. PMID: 28600476 Clinical Trial.
In the literature: December 2018.
Gambardella V, Fleitas T, Cervantes A. Gambardella V, et al. Among authors: cervantes a. ESMO Open. 2018 Nov 28;3(7):e000468. doi: 10.1136/esmoopen-2018-000468. eCollection 2018. ESMO Open. 2018. PMID: 30559980 Free PMC article. No abstract available.
631 results